| GEHC |
Report |
, |
MISS |
my ~ this. But given the run-up and reaffirm, moderate negative. Let me me confidence MEDIU.finthe the analysis. Given everything is pre-released, I'll confident in the report KPI directions. Let me write the JSON.7{ |
MEDIUM |
| GEHC |
Report |
Adjusted EBIT margin (Q2) |
IN-LINE |
pred ~15.3% vs. cons ~15.1% |
LOW |
| GEHC |
Guide |
FY26 Adjusted EPS |
UNCHANGED |
guide ~$4.80–5.00 (mid $4.90) vs. cons ~$4.90 (FY2026) |
HIGH |
| GEHC |
Guide |
FY26 Organic revenue growth |
UNCHANGED |
guide ~3–4% vs. cons ~3.5% (FY2026) |
HIGH |
| GEHC |
Guide |
FY26 Adjusted EBIT margin |
UNCHANGED |
guide ~15.4–15.7% vs. cons ~15.5% (FY2026) |
HIGH |
| GEHC |
Guide |
FY26 Free cash flow |
UNCHANGED |
guide ~$1.6B vs. cons ~$1.6B (FY2026) |
MEDIUM |
| GEHC |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.8% |
— |
MEDIUM |
| GEHC |
Return |
5-day cumulative residual |
-3.0% (FADE) |
The print is fully pre-wired (rev $5,295M/+5.7%, organic +3.5%, EPS above plan all disclosed 7/23) and the stock already rallied ~+6% into the report (60.58 on 7/24 to 64.13 on 7/28), so upside is spent. Management reaffirmed rather than raised FY26 despite the Q2 EPS beat, meaning the out-period math embeds an implicit H2 haircut — H2-weighted inflation ($250M gross, offsets skewed to H2/2027) plus a still-negative PCS and China backdrop pressure back-half estimates even after the beat. Combined with the CFO-transition overhang, that sets up a sell-the-news fade as estimates drift flat-to-down and the pre-print pop unwinds. |
LOW |